LLY's post-market drop offers investment potential with robust R&D, capex strategies, and strong cash flow, positioning it ...

Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...

Even in a softer market, momentum hasn’t stalled. The Boston-Cambridge region still offers what few others can.

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

We recently published a list of the 15 Best Growth Stocks to Buy for the Next 3 Years. In this article, we are going to take ...

Shares of Eli Lilly fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed ...

Ricks said reshoring manufacturing capacity for older essential medicines is “a valid thing,” adding that Eli Lilly is “happy ...

Roche projected that its $50 billion manufacturing investment, to include R&D operations, will generate 1,000 jobs at the ...

Orforglipron, an experimental treatment Eli Lilly is developing for diabetes and weight loss, hit high marks in the first of several pivotal trials. The daily tablet produced blood-sugar ...

But what matters more than Lilly's accomplishments in the past is what the company could do in the future. Where will Eli Lilly be in five years? Where to invest $1,000 right now? Our analyst team ...

While Eli Lilly has a significant presence in the U.S., bringing its developing treatment to market will require stable business conditions. The Indianapolis company on Thursday said its ...

From late 2020 to the summer of 2024, Eli Lilly & Co ... Billions Since 2016, Lilly’s revenue grew by 60% but income grew by 91%. Typically, you would not expect a company growing at its ...